Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine

Riley, Kathryn; Schwager, Zachary; Stern, Marleigh J.; Vleugels, Ruth Ann; Femia, Alisa

doi:10.1001/jamadermatol.2018.5212

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are cases of mild reactions in the form of a measles-like rash, 17 severe skin reactions such as acute generalized exanthematous pustulosis and systemic drug-induced hypersensitivity syndrome or DRESS syndrome ( Drug Rash with Eosinophilia and Systemic Symptoms ) 18 , 19 and anaphylaxis. 20 …”

Section: Hydroxychloroquinementioning

confidence: 99%

Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection

Regás

Culla

Bellfill

2020

Medicina Clínica (English Edition)

View full text Add to dashboard Cite

Currently, there is no treatment approved for COVID-19. Numerous drugs are being used in an empirical manner according to experience and availability. Studies demonstrating their efficacy and safety are still to be published. Thus, it is of vital importance for healthcare workers to be well informed and updated regarding possible immunological and non-immunological adverse effects regarding such treatments. In this narrative revision, the rationale use of these treatments in the SARS-CoV-2 infection is emphasized as well as their most frequently described adverse drug reactions. Drugs that are being essayed to counteract both clinical phases that are thought to take place in the severe stage of this disease are included; an initial phase where a viral infection prevails and a second phase where an inflammatory response takes over. Adverse reactions registered in the Pharmacovigilance Program of our hospital before the onset of this pandemic have also been included.

show abstract

Section: Hydroxychloroquinementioning

confidence: 99%

Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection

Regás

Culla

Bellfill

2020

Medicina Clínica (English Edition)

View full text Add to dashboard Cite

show abstract

“… 43 Chloroquine can be considered as an alternative agent for patients with CLE who cannot tolerate or do not respond to hydroxychloroquine. 44 , 45 Quinacrine can be either added to hydroxychloroquine or chloroquine for patients with incomplete response or used as an alternative agent for patients with retinal toxicity.…”

Section: Introductionmentioning

confidence: 99%

Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases

Goldman¹,

Han²,

LaChance³

2022

CCID

View full text Add to dashboard Cite

The cutaneous features of autoimmune connective tissue disease pose a unique challenge to patients and clinicians managing these conditions. In this review, we outline the key elements of diagnosis and treatment of cutaneous lupus erythematosus, dermatomyositis, systemic sclerosis, and morphea. This article also aims to present an update on gold standard as well as new and emerging therapies for these conditions. Overall, dermatologists can play a key role in diagnosing and treating autoimmune connective tissue diseases and this review intends to provide an up-to-date toolkit to guide clinical dermatologists in this endeavor.

show abstract

Chloroquine

2019

Reactions Weekly

View full text Add to dashboard Cite

Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine

Abstract: The relationship between required medical school instruction in musculoskeletal medicine and application rates to orthopaedic surgery residency programs.

Cited by 4 publications

References 5 publications

Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection

Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection

Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases

Chloroquine

Contact Info

Product

Resources

About